Superior Planning, LLC’s MoonLake Immunotherapeutics MLTX Stock Holding History

Superior Planning, LLC’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$538	Buy	+46	New	+$752	﹤0.01%	1880

Other funds holding MLTX

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Winton Group London, United Kingdom $2.58B AUM 26.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Superior Planning, LLC's MLTX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 46 shares worth $538. The stake represents ﹤0.01% of the portfolio and ranks #1880 among its holdings.

72 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

Superior Planning, LLC held 46 shares of MoonLake Immunotherapeutics worth $538 as of Q3 2026.
MoonLake Immunotherapeutics was a new Superior Planning, LLC position in Q3 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1880 holding.
72 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.